The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice.
We have shown that inhibitors of five lipoxygenase activating protein (FLAP)--MK-886 and BAYx1005 inhibit atherosclerosis in apolipoprotein E/LDL receptor-double knockout mice. We, therefore, investigated whether cysteinyl leukotrienes receptor inhibitor--montelukast, given at a dose of 0.125 microg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR-DKO mouse model montelukast significantly decreased atherogenesis, measured both by "en face" method (25.5+/-2.% vs. 17.23 +/- 1.8%) and "cross-section" method (455,494 +/- 26,477 microm(2) vs. 299,201 +/- 20,373 microm(2)). The results were, however, less pronounced, comparing to FLAP inhibitors. This is the first report showing the effect of montelukast on atherogenesis in gene-targeted mice.
Jawien
J
J
Jagiellonian University School of Medicine, Cracow, Poland. mmjawien@cyf-kr.edu.pl
Gajda
M
M
Wołkow
P
P
Zurańska
J
J
Olszanecki
R
R
Korbut
R
R
D000085:Acetates / Q000627:therapeutic use*; D000818:Animals; D001011:Aorta / Q000473:pathology; D001057:Apolipoproteins E / Q000235:genetics*; D050197:Atherosclerosis / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D003521:Cyclopropanes; D005260:Female; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009206:Myocardium / Q000473:pathology; D011804:Quinolines / Q000627:therapeutic use*; D011973:Receptors, LDL / Q000235:genetics*; D013440:Sulfides; D014280:Triglycerides / Q000097:blood
D000085:Acetates; D001057:Apolipoproteins E; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D008055:Lipids; D011804:Quinolines; D011973:Receptors, LDL; D013440:Sulfides; D014280:Triglycerides; D002784:Cholesterol; C093875:montelukast